CAR Macrophages Generated In Situ via mRNA-Loaded Extracellular Vesicles Show Promise Against Lung Metastasis
Key Insights
Researchers developed a novel approach using small extracellular vesicles (search) (sEVs) to deliver CAR-encoding mRNA (search) directly to lung macrophages, enabling in situ generation of CAR macrophages (search) without ex vivo cell manipulation.
In preclinical murine models, mice treated with CARmRNA@aCD206 sEVs (search) showed significantly reduced tumor burden and 100% survival beyond 60 days compared to controls that succumbed within 30 days.
The engineered CAR macrophages (search) demonstrated antigen-specific tumor phagocytosis, reprogrammed the immunosuppressive tumor microenvironment toward an M1-like state, and established durable immune memory preventing tumor recurrence.
Researchers have developed a groundbreaking approach to combat lung metastasis (search) by engineering macrophages directly within the patient's body using mRNA (search)-loaded extracellular vesicles. This innovative strategy, published in Nature Communications (search) by Xiao et al., represents a significant advancement in cancer (search) immunotherapy that could overcome key limitations of current CAR-T cell therapies.
Novel In Situ CAR Macrophage Generation
The research team created small extracellular vesicles (search) (sEVs) engineered to deliver chimeric antigen receptor (CAR)-encoding mRNA (search) specifically to lung macrophages. Unlike traditional CAR-T therapies that require complex ex vivo cell manipulation, this approach generates therapeutic CAR macrophages (search) directly at the tumor site through targeted mRNA delivery.
The engineered sEVs, designated CARmRNA@aCD206 sEVs (search), were surface-modified with anti-CD206 (search) single-chain variable fragments to specifically target CD206-expressing macrophages within the tumor microenvironment. The vesicles contained anti-mesothelin CAR (search) mRNA (search) packaged through an optimized L7Ae-C/D box interaction system, achieving approximately 693 CAR mRNA copies per 1×10⁶ sEVs.
Robust Anti-Tumor Efficacy in Preclinical Models
In murine lung metastasis (search) models established with B16-MSLN melanoma (search) cells, inhaled CARmRNA@aCD206 sEVs (search) demonstrated remarkable therapeutic efficacy. Approximately 28% of lung macrophages, including both tumor-associated macrophages (TAMs) and alveolar macrophages (AMs), successfully expressed CAR proteins following treatment.
The therapeutic impact was striking: mice treated with CARmRNA@aCD206 sEVs (search) showed dramatically delayed tumor progression compared to all control groups. While PBS and control-treated mice succumbed to metastatic disease within 30 days, 100% of CARmRNA@aCD206 sEV-treated mice survived beyond 60 days post-tumor inoculation. Assessment of tumor burden revealed substantial reductions in both the number and size of pulmonary tumor nodules.
Immune Microenvironment Reprogramming
The engineered CAR macrophages (search) demonstrated multiple anti-tumor mechanisms beyond direct cytotoxicity. Flow cytometric analysis revealed that CARmRNA@aCD206 sEV treatment upregulated CD86 and MHC II expression while downregulating CD206 (search), indicating phenotypic repolarization from immunosuppressive M2-like to immunostimulatory M1-like macrophages.
This reprogramming had profound effects on the tumor microenvironment. Treatment resulted in marked infiltration of cytotoxic CD8+ T cells and granzyme B-expressing CD8+ T cells, while significantly reducing immunosuppressive regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs). Pro-inflammatory cytokines IFN-γ and TNF-α were markedly upregulated, while immunosuppressive cytokines IL-10 and TGF-β were substantially decreased.
Durable Immune Memory and Recurrence Prevention
A critical finding was the system's ability to establish long-term immune memory. Analysis of lymph nodes revealed profound increases in both central memory T cells (TCM) and effector memory T cells (TEM) frequencies in CARmRNA@aCD206 sEV-treated mice compared to controls.
In tumor rechallenge experiments, mice previously cured with CARmRNA@aCD206 sEVs (search) exhibited complete resistance to B16-MSLN tumor rechallenge, with no detectable tumor formation even by day 21. Remarkably, these mice also demonstrated partial resistance to rechallenge with parental B16 cells lacking the CAR target antigen, suggesting epitope spreading through cross-presentation of tumor antigens.
Superior Delivery and Safety Profile
The inhalation delivery route proved superior to intravenous administration for lung targeting. While intravenous injection led to predominant accumulation in liver and spleen, inhaled CARmRNA@aCD206 sEVs (search) showed sustained lung accumulation with detectable levels even at 48 hours post-inhalation.
Comprehensive safety assessments revealed excellent biocompatibility. Biochemical analysis showed liver function indicators (ALT, AST, ALP) and kidney function indicators (UREA, creatinine) remained within normal limits. Histopathological analysis of major organs revealed no obvious pathological abnormalities, and body weights remained stable throughout treatment.
Mechanistic Insights and Targeting Specificity
The research provided detailed mechanistic insights into the delivery system. Confocal microscopy demonstrated that CARmRNA@aCD206 sEV internalization by M2 macrophages was significantly higher than non-targeted controls at both 4 and 24 hours. The presence of anti-CD206 (search) antibodies effectively inhibited sEV internalization, confirming the critical role of CD206 in mediating targeted delivery.
Flow cytometry analysis revealed that macrophages were the predominant immune cells expressing CAR protein following sEV treatment, with minimal expression detected on infiltrating monocytes or peripheral blood monocytes. This highlighted the high specificity of CARmRNA@aCD206 sEVs (search) in selectively targeting the macrophage population within the lung tumor microenvironment.
Clinical Translation Potential
The study addresses several critical limitations of current CAR therapies. The approach eliminates the need for personalized cell collection and manufacturing, enables repeated dosing for therapeutic intensity modulation, and minimizes systemic toxicities by concentrating engineered immune effectors within tumor-bearing organs.
The transient nature of mRNA (search) expression, peaking at 48 hours and declining over subsequent days, reduces risks of insertional mutagenesis or long-term off-target effects associated with viral vector-based gene therapies. The natural origin and biocompatibility of sEVs likely minimize immune reactions against the delivery vehicle itself.
This innovative fusion of synthetic biology, immunology, and nanotechnology represents a paradigm shift from ex vivo cell-based immunotherapies toward biomimetic delivery systems that integrate seamlessly within the patient's immune ecosystem. The approach holds transformative potential not only for lung metastases but also for the broader challenge of treating solid tumors (search) across multiple organs, potentially democratizing access to potent cell-based therapies globally.